March/April

A data-centric approach is vital for patients with complex conditions, particularly in determining what has worked well and anticipating what medical or pharmacy care is required for effective outcomes in the future.

The shift from fee-based, volume-driven care to value-based, patient-centered care and the growth of specialty pharmaceuticals are propelling us all into uncharted territory, no matter what role you play in health care.

Failure to recognize the interests of manufacturers to ensure proper use of 340B pricing may result in 340B hospitals missing the opportunity to secure and retain discounts on key orphan and specialty drugs or may render them unable to access the drugs at all.

The value of big data in health care is realized when raw data are transformed into insights that drive practice change and decision making.

Celgene Corporation’s lenalidomide (Revlimid) is a targeted therapy that stops the growth of myeloma cells in the bone marrow.

This proposal, outlined by the Centers for Medicare & Medicaid Services (CMS) in late 2018, would undermine CMS’ stated goal of prioritizing value and improved patient outcomes over utilization and sickness.

If an assessment of risk is not conducted and implemented on a specific hazardous drug or dosage form, it must be handled according to the standard.

One way that policymakers and industry insiders have constantly considered to lower drug prices has been through importation.

Experts explore current and emerging therapies for hemophilia and review best practices for management of the disease.

For the traditional specialty pharmacy, we often think of oral or self-injectable products being sent to the patient’s home. But what about specialty infused products?

With the first few months of 2019 behind us, one of the signature events in the specialty space is on the horizon.